Additional file 1 of Novel KMT2B gene mutation in MUC4 positive low-grade fibromyxoid sarcoma

Supplementary Material

Influence of clinicopathological characteristics and comprehensive treatment models on the prognosis of small cell carcinoma of the cervix: A systematic review and meta-analysis

<div><p>Small cell carcinoma of the cervix (SCCC) is a rare primary neuroendocrine cervical carcinoma with a high degree of invasiveness. SCCC is prone to early-stage lymph node and distant metastases and characterized by a poor prognosis. Currently, there is no standard treatment. This study aimed to evaluate the clinicopathological factors and treatment models that influence SCCC prognosis through a systematic review and meta-analysis, to improve the diagnosis and treatment of SCCC. A comprehensive search was performed in multiple medical literature databases to retrieve studies on the clinical prognosis of SCCC published in China and abroad as of March 1, 2017. Twenty cohort studies with 1904 patients were analyzed. Meta-analysis showed statistical significance for the following factors: FIGO staging (hazard ratio [HR] = 2.63, 95% confidence interval [CI]: 2.13–3.24; odds ratio [OR] = 3.72, 95% CI: 2.46–5.62), tumor size (HR = 1.64, 95% CI: 1.25–2.15), parametrial involvement (HR = 2.40, 95% CI: 1.43–4.05), resection margin (HR = 4.09, 95% CI: 2.27–7.39), lymph node metastasis (OR = 2.09, 95% CI: 1.18–3.71), depth of stromal invasion (HR = 1.99, 95% CI: 1.33–2.97), neoadjuvant chemotherapy (HR = 2.06, 95% CI: 1.14–3.73), and adjuvant chemotherapy (HR = 1.63, 95% CI: 1.26–2.12; OR = 1.48, 95% CI: 1.02–2.16). FIGO staging, tumor size, parametrial involvement, resection margin, depth of stromal invasion, and lymph node metastasis can be used as clinicopathological characteristics for the prediction of SCCC prognosis. Neoadjuvant chemotherapy tended to improve prognosis. Our findings suggest that neoadjuvant chemotherapy plus adjuvant chemotherapy may be the preferred strategy. However, adjuvant radiotherapy appeared to cause no significant improvement in prognosis. Therefore, the clinical application of radiotherapy and the relationship between radiotherapy and clinicopathological factors need to be re-examined. The results of this study should be validated and developed in formal, well-designed multicenter clinical trials.</p></div

Results of quality assessment using the Newcastle-Ottawa Scale for cohort studies.

<p>Results of quality assessment using the Newcastle-Ottawa Scale for cohort studies.</p

Tumor size.

<p><b>Forest plot of tumor size and overall survival of small cell carcinoma of the cervix patients.</b> SE: standard error; CI: confidence interval.</p

Forest plot of depth of stromal invasion (>2/3/≤1/3/) and overall survival of small cell carcinoma of the cervix patients.

<p>SE: standard error; CI: confidence interval.</p

Forest plot of neoadjuvant chemotherapy (+/-) and overall survival of small cell carcinoma of the cervix patients.

<p>SE: standard error; CI: confidence interval.</p

Forest plot of adjuvant chemotherapy (+/-) and overall survival and survival rate of small cell carcinoma of the cervix patients.

<p>(A) studies reporting hazard ratios; and (B) studies reporting odds ratios. SE: standard error; CI: confidence interval.</p

Forest plot of lymphovascular space invasion (-/+) and overall survival of small cell carcinoma of the cervix patients.

<p>SE: standard error; CI: confidence interval.</p

FIGO (International Federation of Gynecology and Obstetrics) staging.

<p><b>Forest plot of FIGO staging (Ia-IIa/IIb-IV) and overall survival of small cell carcinoma of the cervix patients.</b> (A) The hazard ratios of the analyzed studies; and (B) the odds ratios of the analyzed studies. SE: standard error; CI: confidence interval.</p

Studies eligible for inclusion in the meta-analysis.

<p>CKNI: China national knowledge infrastructure; CBM: China biology medicine.</p